Farxiga DAPA-CKD Phase III trial reduced worsening of kidney function, risk of cardiovascular or renal death in patients with chronic kidney disease, irrespective of underlying cause.- AstraZeneca

In the subgroup analysis, compared to placebo Farxiga showed a relative risk reduction (RRR) of 37% for patients whose CKD was primarily driven by diabetic kidney disease (absolute risk reduction [ARR] = 5.8%); 25% for high blood pressure (ARR = 2.2%); 57% for glomerulonephritis (ARR = 7.5%); and 42% for CKD of other or unknown causes (ARR = 5.0%) (p?interaction for RRR 0.53).1 Similarly, Farxiga showed a reduction in all-cause mortality, a secondary outcome, compared to placebo regardless of underlying CKD cause (p-interaction 0.55). The safety and tolerability of Farxiga was consistent with the well-established safety profile of the medicine. The data were presented at the American Society of Nephrology (ASN) Kidney Week Reimagined 2020.